Chemotherapy News and Research

Latest Chemotherapy News and Research

Lixte receives $244,479.25 U.S. government grant for QTDP program

Lixte Biotechnology Holdings announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project.

3 Mar 2011

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

3 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Additional pathology tests can improve survival rates in patients with oesophageal cancer

A University of Adelaide medical researcher says current treatment for people diagnosed with oesophageal cancer could be improved with additional pathology tests.

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Cancer Research UK scientists have made an important step towards developing personalised bowel cancer treatment by identifying which tumours are more likely to become drug resistant, according to research published in Cancer Research today.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival

Researchers from Boston University School of Medicine (BUSM) have found that patients with node negative T3 and T4 non-small lung cancer who underwent chemotherapy before surgery had more than three times the survival rate than patients who only underwent surgery. These findings currently appear on-line in the Journal of Thoracic and Cardiovascular Surgery.

1 Mar 2011

Mindray Medical enters agreement to acquire controlling stake of Shenke

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Shenzhen Shenke Medical Instrument Technical Development Co. Ltd. The terms of the transaction were not disclosed as the transaction is non-material to Mindray's financial statements.

From Mindray 28 Feb 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that fish oil may help combat cancer-related malnutrition.

28 Feb 2011

Innovative miniscule gene transport system can cause breast cancer cells to self-destruct

Scientists at Queen's University Belfast have shown that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using an innovative, miniscule gene transport system, according to research published today in the International Journal of Pharmaceutics.

28 Feb 2011

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Avastin debate spills over until June FDA hearing

The U.S. Food and Drug Administration have granted Roche a hearing in June to defend the cancer treatment Avastin. The hearing would examine the effectiveness of the drug in breast cancer.

27 Feb 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Lixte receives $244,479.25 U.S. government grant for QTDP program

Scientists discover genetic process that may allow ovarian cancer to resist chemotherapy

Mathematical model predicts lifespan of stem cells

Additional pathology tests can improve survival rates in patients with oesophageal cancer

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

New personalized therapy fools cancer cells into killing themselves

Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival

Mindray Medical enters agreement to acquire controlling stake of Shenke

TCD announces first patient treated in its TCD-717 Phase I trial

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

Innovative miniscule gene transport system can cause breast cancer cells to self-destruct

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Avastin debate spills over until June FDA hearing

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in